文献速递乳腺癌骨软组织肉瘤与黑色素瘤

LY3039478(口服Notch信号抑制剂)在晚期或转移性癌症中的首次人体研究

First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer.
PubMed 文献 · Ann Oncol · 2018-01-01

这是一项I期开放标签多中心非随机剂量递增研究,评估口服Notch抑制剂LY3039478在晚期或转移性癌症患者中的安全性、药代动力学、药效动力学和抗肿瘤活性。110例患者接受单药治疗,剂量限制性毒性为血小板减少、结肠炎和恶心,推荐II期剂量为50 mg每周三次。在乳腺癌、平滑肌肉瘤和腺样囊性癌中观察到临床活性。

要点

  • 推荐II期剂量为50 mg每周三次,因耐受性优于75 mg。
  • 剂量限制性毒性为血小板减少、结肠炎和恶心,不良事件多为胃肠道反应。
  • 在乳腺癌、平滑肌肉瘤和腺样囊性癌中观察到临床活性。

核心结论

  • LY3039478对Notch信号的有效抑制在靶点结合剂量下耐受良好,并在重度经治患者中显示临床活性证据。

研究设计与样本

  • I期、开放标签、多中心、非随机、剂量递增研究,共110例晚期或转移性癌症患者接受LY3039478单药治疗。
  • 给药方案为口服2.5-100 mg,每周三次(TIW),28天为一周期。

主要发现

  • 剂量限制性毒性为血小板减少、结肠炎和恶心,大多数不良事件为胃肠道反应。
  • 药代动力学呈剂量比例关系。
  • 药效动力学数据显示在45-100 mg剂量下血浆Aβ抑制约80%,Notch调控基因HES1、cyclin D1和NRARP抑制>50%。
  • 在乳腺癌、平滑肌肉瘤和腺样囊性癌患者中观察到临床活性(肿瘤坏死、代谢反应或肿瘤缩小)。

关键数值与推荐

  • 推荐II期剂量为50 mg每周三次,因耐受性优于75 mg。

临床怎么用

  • LY3039478单药在靶点结合剂量下耐受良好,可考虑进一步研究其单药及联合靶向药物或化疗的疗效。

局限性

  • 为I期非随机剂量递增研究,样本量有限,抗肿瘤活性为初步观察。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Deregulated Notch signaling due to mutation or overexpression of ligands and/or receptors is implicated in various human malignancies. γ-Secretase inhibitors inhibit Notch signaling by preventing cleavage of transmembrane domain of Notch protein. LY3039478 is a novel, potent Notch inhibitor decreases Notch signaling and its downstream biologic effects. In this first-in-human study, we report the safety, pharmacokinetic (PK) profile, pharmacodynamic effects, and antitumor activity of LY3039478 in patients with advanced or metastatic cancer. METHODS: This phase I, open-label, multicenter, nonrandomized, and dose-escalation phase study determined and confirmed the recommended phase II dose of LY3039478 (oral dose: 2.5-100 mg, thrice weekly (TIW) on a 28-day cycle). The primary objectives are to determine (part A) and confirm (part B) a recommended phase II dose that may be safely administered to patients with advanced or metastatic cancer, and secondary objectives include evaluation of safety, tolerability, PK parameters, and preliminary antitumor activity of LY3039478. RESULTS: A total of 110 patients were treated with LY3039478 monotherapy between 31 October 2012 and 15 July 2016. Dose-limiting toxicities were thrombocytopenia, colitis, and nausea. Most adverse events were gastrointestinal. The recommended phase II dose was 50 mg TIW, because of its better tolerability compared with 75 mg. The PKs of LY3039478 appeared dose proportional. Pharmacodynamic data indicate an ∼80% inhibition of plasma Aβ, and >50% inhibition of Notch-regulated genes hairy and enhancer of split-1, cyclin D1, and Notch-regulated ankyrin repeat at 45-100-mg dose. Clinical activity (tumor necrosis, metabolic response, or tumor shrinkage) was observed in patients with breast cancer, leiomyosarcoma, and adenoid cystic carcinoma. CONCLUSION: Potent inhibition of Notch signaling by LY3039478 was well tolerated at doses associated with target engagement, and demonstrated evidence of clinical activity in heavily pretreated patients. Further investigation with LY3039478 as monotherapy and in combination with targeted agent or chemotherapy is ongoing. CLINICALTRIALS.GOV ID: NCT01695005.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Massard C, Azaro A, Soria JC, et al. First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer. Ann Oncol. 2018. PMID: 30060061. doi:10.1093/annonc/mdy244

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。